The prescribing monitoring suite of searches has undergone extensive review by our team of GPs and pharmacists in accordance with current guidelines.  We plan to publish an updated version on 24th September 2024.

 

We host a link to a document that outlines the tests suggested as part of Ardens Drug Monitoring System, and the guidance that has been referred to. 

 

Below is a summary of changes that Ardens SystmOne users may notice.  For example, where monitoring has been added, a patient may appear as overdue despite attending recently for their monitoring blood tests.  If local resources have been created linking to an Ardens report, these will produce error messages when the reports are deleted.


 

The following have been removed due to altered or lack of clear guidance:

  • DRI (aliskiren) | No UE in last 1y
  • On DOAC | No BP in last 1y
  • On NSAID and >2 issues in last 1y | No UE in last 1y
  • On calcitriol | No UE, LFT, Ca, PTH, Mg, Phos in last 4w + HRD Primary care monitoring
  • On hydroxychloroquine | No UE in last 1y (if >70y, CKD, HTN, DM) (exc sec care)
  • On warfarin | No FBC, UE or LFT in last 1y
  • On pioglitazone | No LFT in last 1y
  • On propylthiouracil | No LFT in last 1y

 

The following have also been added or amended due to new NICE, NHSE or SPS guidance:

 

  • Atomoxetine, dexamfetamine, lisdexamfetamine & methylphenidate - Height only requested if <18 years

            On atomoxetine <18y | No BP, HR, height or weight in last 6m

            On dexamfetamine <18y | No BP, HR, height or weight in last 6m

            On lisdexamfetamine <18y | No BP, HR, height or weight in last 6m

            On methylphenidate <18y | No BP, HR, height or weight in last 6m

 

  • Guanfacine - Added BP, HR + height if <18 years

            On guanfacine <18y | No BP, HR, height or weight in last 6m

 

  • Amiodarone - Add Mg.  TFT must include T3 T4 + TSH

            On amiodarone | No UE, Mg, LFT or TFT (T3, T4,and TSH) in last 6m

 

  • Digoxin - Add calcium + magnesium

            On digoxin | No UE, Ca or Mg in last 1y

 

  • Diuretic - Frequency for UE increased to 6m from 1y. Previously thiazide and loop were annually.

            On diuretic - excluding thiazide | No UE in last 6m

 

  • Dronedarone - Frequency for UE + LFT increased to 6m from 1y

            On dronedarone | No UE or LFT in last 6m

 

  • Propylthiouracil - TSH monitoring frequency increased from 6m to 3m

            On propylthiouracil | No TSH in last 3m

 


Invite reports

The monitoring invite reports will undergo a restructure to align with other invite reports across the Ardens system. There will be a separate invite report with cohorts of people you may wish to alter their invitation method or review before inviting. These will be released in a second phase of the roll-out, and further details will be provided in due course.